NCT07294235

A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of BGM1812 in Healthy and Non-diabetic Overweight or Obese Chinese Participants

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: BrightGene Bio-Medical Technology Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	BGM1812	AdministeredSC
DRUG	Placebo	Administered SC
DRUG	BGM1812	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2025-12-05
• Primary completion: 2026-03-02
• Completion: 2026-03-02
• First posted: 2025-12-19
• Last updated: 2025-12-19

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study